Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 16/20 | 0.65 |
| ▸ | MAPK10 | P53779 | 8/20 | 0.65 |
| ▸ | MAPK8 | P45983 | 7/20 | 0.65 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 9/20 | 0.44 |
| ▸ | GSK3A | P49840 | 2/20 | 0.42 |
| ▸ | BUB1 | O43683 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18431264 | 0.87 | MAPK14 (0.60) | MAPK14MAPK10MAPK8PIP5K1CPIK3CA | |
| SCHEMBL12627466 | 0.87 | MAPK14 (0.60) | MAPK14MAPK10MAPK8PIP5K1CPIK3CA | |
| SCHEMBL1518805 | 0.81 | MAPK10 (1.00) | MAPK14MAPK10MAPK8PIP5K1CPIK3CA | |
| SCHEMBL21068073 | 0.81 | MAPK10 (1.00) | MAPK14MAPK10MAPK8PIP5K1CPIK3CA | |
| SCHEMBL17223597 | 0.81 | MAPK10 (1.00) | MAPK14MAPK10MAPK8PIP5K1CPIK3CA | |
| SCHEMBL12627476 | 0.80 | MAPK14 (0.59) | MAPK14MAPK10MAPK8PIP5K1CPIK3CA | |
| SCHEMBL18431826 | 0.80 | MAPK14 (0.59) | MAPK14MAPK10MAPK8PIP5K1CPIK3CA | |
| SCHEMBL12627470 | 0.79 | MAPK14 (0.60) | MAPK14MAPK10MAPK8PIP5K1CPIK3CA | |
| SCHEMBL18431823 | 0.79 | MAPK14 (0.60) | MAPK14MAPK10MAPK8PIP5K1CPIK3CA | |
| SCHEMBL12656770 | 0.78 | MAPK14 (0.67) | MAPK14MAPK10MAPK8PIP5K1CPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110117073-A1 | Protein Kinase Conjugates and Inhibitors | AVILA THERAPEUTICS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117073-A1 | Protein Kinase Conjugates and Inhibitors | MAP3K20, PACSIN2, MAP3K9 | MAPK14 296/4885MAPK10 294/4885MAPK8 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.